SLC22A31: A Potential Drug Target and Biomarker (G146429)

Target Name: SLC22A31

NCBI ID: G146429

Other Name(s): solute carrier family 22 member 31 | Solute carrier family 22, member 31 | Putative solute carrier family 22 member 31 | S22AV_HUMAN | putative solute carrier family 22 member ENSG00000182157 | Putative solute carrier family 22 member ENSG00000182157 | Solute carrier family 22 member 31

SLC22A31: A Potential Drug Target and Biomarker

SLC22A31 is a protein that belongs to the SLC22A family, which is a well-known transmembrane protein family that is involved in various physiological processes in the body. SLC22A31 is a 31 kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys.

SLC22A31 functions as a solute carrier protein, which means that it helps to transport solutes, such as ions and molecules, across the membrane of the cell. This protein is essential for maintaining the proper functioning of many physiological processes in the body, including the regulation of ion and water balance, as well as the transport of various substances across the membrane of the cell.

One of the unique features of SLC22A31 is its expression pattern in different tissues of the body. This protein is highly expressed in the brain, where it is involved in the regulation of ion and water balance, as well as the transport of various substances, including glucose and amino acids. It is also expressed in the heart and kidneys, where it is involved in the regulation of ion and water balance, as well as the transport of various substances across the membrane of the cell.

SLC22A31 is also known as a drug target or biomarker, which means that it is a protein that is targeted by drugs in the treatment of various diseases. This protein is a potential drug target for a variety of diseases, including diabetes, heart disease, and neurodegenerative diseases.

One of the potential reasons why SLC22A31 is a drug target is its involvement in the regulation of ion and water balance. Diabetes is a disease that is characterized by the improper functioning of the immune system, which leads to the destruction of insulin-producing cells in the pancreas. This leads to a lack of insulin in the body, which can cause a variety of negative effects, including high blood sugar levels, nerve damage, and heart disease. SLC22A31 is involved in the regulation of ion and water balance in the brain, which is important for the proper functioning of the immune system. Therefore, SLC22A31 may be a potential drug target for the treatment of diabetes.

Another potential reason why SLC22A31 is a drug target is its involvement in the regulation of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These diseases are often treated with drugs that aim to slow down or halt the progression of neurodegeneration. SLC22A31 is involved in the regulation of ion and water balance in the brain, which is important for the proper functioning of the immune system. Therefore, SLC22A31 may be a potential drug target for the treatment of neurodegenerative diseases.

SLC22A31 is also a biomarker, which means that it is a protein that is used to diagnose or monitor a medical condition. This protein can be used as a biomarker for a variety of diseases, including diabetes, heart disease, and neurodegenerative diseases. For example, SLC22A31 can be used as a biomarker for the diagnosis of diabetes by measuring its expression level in the body.

In conclusion, SLC22A31 is a protein that is involved in various physiological processes in the body, including the regulation of ion and water balance, the transport of solutes across the membrane of the cell, and the regulation of neurodegenerative diseases. As a result, SLC22A31 is a potential drug target and a biomarker for the treatment of various diseases, including diabetes, heart disease, and neurodegenerative diseases. Further research is needed to fully understand the role of SLC22A31 in the regulation of physiological processes in the body and its potential as a drug

Protein Name: Solute Carrier Family 22 Member 31

Functions: Organic anion transporter that mediates the uptake of ions

More Common Targets